PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27149910-0 2016 Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. Diltiazem 95-104 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 37-43 32803289-8 2021 CONCLUSION: Moderate effect of diltiazem on tacrolimus sparing, which might relate to the polymorphisms of CYP3A4, CYP3A5, ABCB1, and SLCO1B3, was documented. Diltiazem 31-40 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 115-121 27149910-10 2016 WHAT IS NEW AND CONCLUSION: The CYP3A4*1G and CYP3A5*3 genetic polymorphisms are closely related to the trough concentration/dose ratios and pharmacokinetics of diltiazem and its main metabolites in Chinese adult renal transplant patients. Diltiazem 161-170 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 46-52 30471066-10 2019 In contrast, among CYP3A5 expressors receiving diltiazem, AUCss, 0-24 did not change significantly upon conversion [229 (170-296) vs. 221 (123-342) ng h/mL, p = 0.575, n = 10]. Diltiazem 47-56 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 19-25 27149910-3 2016 This study was carried out to investigate the impacts of the CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the trough concentration/dose ratios and pharmacokinetics of diltiazem and its main metabolites in Chinese adult renal transplant patients. Diltiazem 170-179 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 75-81 27149910-7 2016 RESULTS AND DISCUSSION: The dose-adjusted concentrations and pharmacokinetics of diltiazem and its main metabolites were significantly affected by CYP3A4 *1G and CYP3A5*3 alleles. Diltiazem 81-90 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 162-168 27149910-9 2016 The dose-adjusted trough levels and AUC of diltiazem and its main metabolites were significantly lower in CYP3A5*1*1 carriers than in CYP3A5*3 carriers (P < 0 05). Diltiazem 43-52 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 106-112 27149910-9 2016 The dose-adjusted trough levels and AUC of diltiazem and its main metabolites were significantly lower in CYP3A5*1*1 carriers than in CYP3A5*3 carriers (P < 0 05). Diltiazem 43-52 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 134-140 23432535-9 2013 Results showed that CYP3A5 expressers needed more tacrolimus to reach therapeutic concentration window and were more susceptible to diltiazem-induced concentration increase than CYP3A5 non-expressers. Diltiazem 132-141 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 20-26 23700791-0 2013 Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects. Diltiazem 77-86 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 11-17 23700791-1 2013 PURPOSE: To assess the possibility of using CYP2D6 10 +/- CYP3A5*3 as biomarkers to predict the pharmacokinetics of diltiazem and its two metabolites among healthy Chinese subjects. Diltiazem 116-125 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 58-64 15377640-1 2004 The objectives of this study were to characterize and compare the reversible inhibition and time-dependent inactivation of cytochromes P450 3A4 and 3A5 (CYP3A4 and CYP3A5) by erythromycin, diltiazem, and nicardipine. Diltiazem 189-198 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 164-170 20514078-0 2011 Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Diltiazem 11-20 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 70-76 20514078-2 2011 In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). Diltiazem 49-58 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 154-160 20514078-2 2011 In retrospective study, when coadministered with diltiazem, mean increments in dose-adjusted C(0D7), C(max) and AUC(0-12 h) for tacrolimus were larger in CYP3A5 expressers than in CYP3A5 nonexpressers (48.7 vs 3.7%, 31.7 vs 17.2% and 38.2 vs 18.5%, respectively). Diltiazem 49-58 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 180-186 20514078-4 2011 For CYP3A5 expressers, an algorithm guided by CYP3A5 and diltiazem significantly reduced tacrolimus maintenance dosage (P=0.009) and improved the accuracy of tacrolimus initial dose, resulting in reduction in out-of-range C(0) after initial dose (P=0.002) and dose adjustments (P=0.004). Diltiazem 57-66 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 4-10 20514078-6 2011 Our study results show that CYP3A5 genotype-guided tacrolimus-diltiazem combination is a promising therapy in renal transplant recipients in the early postoperative stage. Diltiazem 62-71 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 28-34 21356216-3 2011 MAIN METHODS: Diltiazem N-demethylase activity of recombinant CYP3A4, CYP3A5, CYP3A7, and human liver microsomes (HLMs) in the presence of cannabinoids was determined. Diltiazem 14-23 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 70-76 18589174-6 2008 Among 18 TAC-treated recipients, all receiving Diltiazem (DTZ), the median C/D ratio was lower for CYP3A5 *1/*1 versus *1/*3 versus *3/*3 (1.9, 4.6, and 13.5 ng/mL per 0.1 mg/kg/d, respectively; P = .001). Diltiazem 47-56 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 99-105 18589174-6 2008 Among 18 TAC-treated recipients, all receiving Diltiazem (DTZ), the median C/D ratio was lower for CYP3A5 *1/*1 versus *1/*3 versus *3/*3 (1.9, 4.6, and 13.5 ng/mL per 0.1 mg/kg/d, respectively; P = .001). Diltiazem 58-61 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 99-105 16024008-0 2005 Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. Diltiazem 70-79 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 15-21 16024008-8 2005 CONCLUSION: The results suggest that CYP3A5*3 has only a minor effect on the pharmacokinetics and metabolism of diltiazem. Diltiazem 112-121 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 37-43 15377640-11 2004 In conclusion, erythromycin, diltiazem, and nicardipine were weaker inhibitors of CYP3A5 and inactivated the enzyme at a slower rate than their respective effects on CYP3A4. Diltiazem 29-38 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 82-88 15499178-6 2004 In addition, the correlation coefficients of CYP3A5 contents with the rates of diltiazem N-demethylation, midazolam 1"-hydroxylation and testosterone 6beta- hydroxylation were higher than those of CYP3A4, although the value of CYP3A5 with the midazolam 4-hydroxylation rate was similar to that of CYP3A4. Diltiazem 79-88 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 45-51 15499178-8 2004 The apparent V(max)/K(m) values for recombinant CYP3A5 indicated the greater contributions to diltiazem N-demethylation and midazolam 1"-hydroxylation as compared with CYP3A4. Diltiazem 94-103 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 48-54 15499178-9 2004 These results suggest that polymorphic CYP3A5 contributes markedly to the drug oxidations, particularly diltiazem N-demethylation, midazolam 1"- hydroxylation and testosterone 6beta-hydroxylation by liver microsomes from Japanese subjects. Diltiazem 104-113 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 39-45